Skip to Main content Skip to Navigation
Journal articles

Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target

Abstract : Patients with ALS show, in addition to the loss of motor neurons in the spinal cord, brainstem, and cerebral cortex, an abnormal depletion of energy stores alongside hypermetabolism. In this study, we show that bioenergetic defects and muscle remodeling occur in skeletal muscle of the SOD1G93A mouse model of ALS mice prior to disease onset and before the activation of muscle denervation markers, respectively. These changes in muscle physiology were followed by an increase in energy expenditure unrelated to physical activity. Finally, chronic treatment of SOD1G93A mice with Ranolazine, an FDA-approved inhibitor of fatty acid β-oxidation, led to a decrease in energy expenditure in symptomatic SOD1G93A mice, and this occurred in parallel with a robust, albeit temporary, recovery of the pathological phenotype.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03376305
Contributor : Stéphane Dieterle Connect in order to contact the contributor
Submitted on : Wednesday, October 13, 2021 - 2:02:04 PM
Last modification on : Wednesday, November 3, 2021 - 2:21:11 PM
Long-term archiving on: : Friday, January 14, 2022 - 7:03:04 PM

File

1-s2.0-S2589004220302728-main....
Publication funded by an institution

Identifiers

Collections

Citation

Silvia Scaricamazza, Illari Salvatori, Giacomo Giacovazzo, Jean Philippe Loeffler, Frederique Renè, et al.. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target. iScience, Elsevier, 2020, 23 (5), pp.101087. ⟨10.1016/j.isci.2020.101087⟩. ⟨inserm-03376305⟩

Share

Metrics

Record views

11

Files downloads

24